<DOC>
	<DOCNO>NCT02065869</DOCNO>
	<brief_summary>This study evaluate pediatric patient malignant non-malignant blood cell disorder blood stem cell transplant deplete T cell receptor ( TCR ) alfa beta cell come partially match family donor . The study ass whether immune cell , call T cell , family donor , specially grown laboratory give back patient along stem cell transplant help immune system recover faster transplant . As safety measure T cell program self-destruct switch destroy start react tissue ( Graft versus host disease ) .</brief_summary>
	<brief_title>Safety Study Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant</brief_title>
	<detailed_description>This Phase 1/2 study evaluate safety feasibility BPX-501 T cell infuse partially mismatch , relate , TCR alpha beta T cell deplete hematopoietic stem cell transplant ( HSCT ) pediatric patient . The purpose clinical trial determine whether BPX-501 infusion enhance immune reconstitution retain graft versus leukemia ( GVL ) effect , potential reduce severity duration severe acute GvHD . The trial evaluate treatment GvHD infusion dimerizer drug ( AP1903 ) subject present Grade III-IV acute GVHD , well subject Grade II gut/liver GvHD Grade I/II GvHD ( skin ) progress respond within 7 day standard care treatment .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Children lifethreatening hematological malignancy , deem eligible allogeneic stem cell transplantation Children nonmalignant disorder amenable cure allograft Lack HLA identical donor Life expectancy &gt; 10 week Lansky/Karnofsky score &gt; 50 , WHO &gt; 4 Grade &gt; II acute GvHD chronic extensive GvHD time inclusion Patient receive immunosuppressive treatment GvHD treatment time inclusion Dysfunction liver ( ALT/AST &gt; 5 time normal value , bilirubin &gt; 3 time normal value ) , renal function ( creatinine clearance &lt; 30 ml / min ) Severe cardiovascular disease ( arrhythmias require chronic treatment , congestive heart failure leave ventricular ejection fraction &lt; 40 % ) Current active infectious disease ( include positive HIV serology viral RNA ) Serious concurrent uncontrolled medical disorder Pregnant breast feed female patient Lack parent ' inform consent</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>hematologic neoplasm</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>primary immune deficiences</keyword>
</DOC>